Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 586529

Next Previous
Drug Profile

GSK 586529

Alternative Names: 586529; GSK586529

Latest Information Update: 01 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Neurocrine Biosciences
  • Developer GlaxoSmithKline
  • Class Antidepressants; Anxiolytics; Small molecules
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Depressive disorders

Most Recent Events

  • 26 Jun 2012 Discontinued - Phase-I for Anxiety disorders in USA (PO)
  • 26 Jun 2012 Discontinued - Phase-I for Depressive disorders in USA (PO)
  • 05 Feb 2008 Phase-I clinical trials in Anxiety disorders in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top